Bioengineered MSC-derived exosomes in skin wound repair and regeneration

Abstract

Refractory skin defects such as pressure ulcers, diabetic ulcers, and vascular ulcers represent a challenge for clinicians and researchers in many aspects. The treatment strategies for wound healing have high cost and limited efficacy. To ease the financial and psychological burden on patients, a more effective therapeutic approach is needed to address the chronic wound. MSC-derived exosomes (MSC-exosomes), the main bioactive extracellular vesicles of the paracrine effect of MSCs, have been proposed as a new potential cell-free approach for wound healing and skin regeneration. The benefits of MSC-exosomes include their ability to promote angiogenesis and cell proliferation, increase collagen production, regulate inflammation, and finally improve tissue regenerative capacity. However, poor targeting and easy removability of MSC-exosomes from the wound are major obstacles to their use in clinical therapy. Thus, the concept of bioengineering technology has been introduced to modify exosomes, enabling higher concentrations and construction of particles of greater stability with specific therapeutic capability. The use of biomaterials to load MSC-exosomes may be a promising strategy to concentrate dose, create the desired therapeutic efficacy, and maintain a sustained release effect. The beneficial role of MSC-exosomes in wound healing is been widely accepted; however, the potential of bioengineering-modified MSC-exosomes remains unclear. In this review, we attempt to summarize the therapeutic applications of modified MSC-exosomes in wound healing and skin regeneration. The challenges and prospects of bioengineered MSC-exosomes are also discussed.

1 Introduction

Wounds are an underestimated health problem that lay a great financial burden on patients and healthcare systems (Frykberg and Banks, 2015). As the primary immune barrier against external damage, the skin is the largest organ in the human body that can regulate thermostability and sense extrinsic stimuli (Takeo et al., 2015). The wound healing process is complex and involves inflammation, cell migration, angiogenesis, and granulation tissue formation, and remodelling of the extracellular matrix (ECM) (Cavanagh et al., 2005; Gushiken et al., 2021). A chronic wound, however, is commonly characterized by prolonged inflammation, persistent infection, the formation of microbial biofilms and failure of epithelial cells respond to stimuli (Schultz et al., 2003; Frykberg and Banks, 2015). According to their etiology, the chronic wounds can be classified as diabetic ulcers, pressure ulcers, and vascular ulcers (Nunan et al., 2014). Due to the healing process’s intricacies, treating chronic wounds is still a great challenge for clinicians.

Exosomes derived from mesenchymal stem cells (MSC-exosomes) with regenerative and immunomodulatory functions have been shown to be beneficial in wound healing and to accelerate the process (Casado-Díaz et al., 2020). Compared with conventional treatment methods, MSC-exosome-based therapies have shown higher therapeutic efficacy that play a role throughout all stages of wound healing (Vu et al., 2021). In addition, MSC-exosome-based therapies avoid the risks of immune rejection and tumorigenesis associated with stem cell transplantation (Yin et al., 2019). Therefore, MSC-exosome-based therapy is considered to be a promising therapeutic approach in wound repair and skin regeneration.

In clinical settings, the application of exosome-based therapy may still face some challenges. The challenging task of isolation, purification, and large-scale production of exosomes represents a direct obstacle to the development of exosome-based treatment from bench to bed (Riau et al., 2019). Exosomes may also undergo rapid clearance in the blood circulation or show poor retention at the wound surface (Agrahari et al., 2016; Riau et al., 2019). In addition, safety concerns have limited the clinical applications of MSC-exosomes. The introduction of bioengineering technologies into MSC-exosome-based therapies is expected to address the practical problems mentioned above.

Ideally, modified exosomes could be loaded with luminal cargos or display specific surface molecules, thereby increasing the efficiency of the exosomes and giving them additional therapeutic effects (Riazifar et al., 2017; Wiklander et al., 2019; Salunkhe et al., 2020). Genetic engineering of progenitor cells and direct modification of exosomes are the main engineering strategies for altering exosomes and increasing their regenerative effectiveness (Luan et al., 2017; Shi et al., 2020a). Other strategies such as engineering of hybrid exosomes may also be used in exosome modification (Chen et al., 2020). Furthermore, encapsulating exosomes into hydrogel scaffolding can be used to form a sustained release system or wound dressing (Liang et al., 2019; Bai et al., 2022; Hu et al., 2022). Preclinical studies and clinical trials of chronic wound models have shown promising results, demonstrating that modified MSC-exosomes could promote angiogenesis, fibrogenesis, re-epithelization, and granulation tissue formation, as well as attenuating inflammation (Shi et al., 2020b; Li et al., 2020; Wu et al., 2021a; Xiong et al., 2022). The application of hydrogels may have a synergistic effect in wound closure (Das et al., 2022). Despite a lack of systematic evidence, bioengineered modified MSC-exosomes are increasingly recognized as beneficial to compensate for the limitations of natural exosome-based clinical therapies in wound healing applications.

In this review, we focus on promising bioengineering modifications of MSC-exosomes that enhance their potential therapeutic effectiveness in wound healing and skin regeneration. The applications of biomaterials loaded with modified MSC-exosomes in wound dressing strategies are also addressed. Finally, the challenges and prospects of tissue-engineered MSC-exosomes are discussed. We hope to provide a valuable overview of the role and the mechanisms of modified MSC-exosomes in cutaneous wound healing and elaborate on the potential of applying modified MSC-exosomes in clinical practice.

2 Wound healing and regenerative management

The primary molecular regulators of wound healing are proteins and polypeptides including growth factors, cytokines, and chemokines (Das et al., 2015; Guo et al., 2018; Kim et al., 2019; Su et al., 2019). During the past decades, with advances in regenerative medicine, significant efforts have been made to explore solutions to improve the tissue regeneration process, thereby repairing and correcting physiological deficiencies. Such approaches include using growth factors, stem cells, and biomaterials to induce a more effective healing process. However, despite promising therapeutic results in preclinical studies, the clinical applications of these strategies have been limited by concerns including tissue origin, standards for isolation and culture procedures, tumorigenicity, and ethical regulatory restrictions on the use of stem cells.

As stem cells have self-renewal capacity and multi-lineage differentiation potential, they have been extensively explored with respect to their potential applications in treatment of chronic wounds (Donati and Watt, 2015; Chen et al., 2016). However, the immunogenicity and tumorigenesis of stem cells are critical factors affecting their therapeutic function. Owing to their comparatively low immunogenicity, MSCs represent a promising source for cell-based therapies for wound healing (Lee et al., 2014). Accumulating evidence demonstrates that the multi-lineage differentiation of MSCs and their secretion of bioactive factors have potential therapeutic value in the treatment of various diseases (Pittenger et al., 1999; Zhou et al., 2021). However, despite promising results in preclinical studies and clinical trials, MSCs fall short of expectations in clinical settings.

The main limiting factors in the therapeutic use of MSCs are their heterogeneity and limited homing capacity in damaged tissue (Ullah et al., 2019; Levy et al., 2020). On the one hand, MSCs may undergo senescence during extended culture (Fang et al., 2018; Tabibzadeh, 2022). On the other hand, the transplantation of MSCs could induce tumorigenic scenarios. The most critical issue is that the preparation process of MSCs remains experimentally challenging. It is also difficult to reproduce the therapeutic potency of an MSC.

Previous research has attributed the therapeutic effects of MSC-based therapies to the multi-lineage differentiation and engrafting capacities of the MSCs. The current view is that the release of extracellular vesicles (EVs) through paracrine mechanisms is the major mediator of their therapeutic activities (Lener et al., 2015; Li et al., 2018a; Zhang et al., 2019a). Various in vitro studies and preclinical disease models have reported that EVs isolated from MSCs cultures display therapeutic activities that equivalent to those of MSCs (Giebel et al., 2017). Therefore, the secretome from MSCs has attracted much attention for its potential use in tissue repair and regeneration.

3 EVs from MSCs

3.1 EV biogenesis

The term “extracellular vesicles” refers to a group of cell-derived lipid bilayer membranous structures containing transmembrane proteins and RNAs (Lötvall et al., 2014; Théry et al., 2018; Mathieu et al., 2019). Work in the late 1960s first discovered and recorded the presence of vesicles around cells in human plasma (Wolf, 1967). However, the generic term “exosome” was not proposed until 1987 (Johnstone et al., 1987). According to their biogenesis processes, EVs can be classified into three major subtypes: (a) microvesicles, budding from the plasma membrane, with size between 50 and 1000 nm; (b) exosomes: a group of relatively smaller membrane vesicles (30–120 nm) secreted from the endosomal system and formed through the inward budding of multivesicular bodies (MVBs) that transfer molecules into target cells; and (c) apoptotic bodies: derived from fragments of apoptotic cells, sized between 800 and 5,000 nm. As there is no standard production protocol for MSC-EVs, the term “MSC-exosomes” was used to describe exosome-containing products derived from MSCs (Gimona et al., 2021).

The biogenesis of exosomes comprises an endosomal sorting complex required for transport (ESCRT)-dependent mechanism and an ESCRT-independent mechanism (Trajkovic et al., 2008; Kajimoto et al., 2013; Mathieu et al., 2019). The ESCRT-dependent process starts with the inward budding of the bilayer membrane of late endosomes, resulting in the formation of intraluminal vesicles. The bilayer membrane bubble-filled endosome is called an MVB. The maturation of MVBs ends with the excretion of the exosomes into the extracellular space. The ESCRT-independent mechanism can also produce intraluminal vesicles. The biogenesis of microvesicles mainly involves the outward budding of the cell plasma membrane and degradation of the cytoskeleton (Shao et al., 2018). However, other mechanisms may be also involved in the biogenesis of microvesicles, for instance, conversion between ceramide and sphingomyelins (van Niel et al., 2018).

3.2 EV isolation and characterization

Differential ultracentrifugation is the most frequently used method for isolation of EVs and remains the “gold standard” (Théry et al., 2018). However, differential ultracentrifugation, which can only be performed for up to about 500 ml of culture medium per run, is unsuitable for large-scale purification (Witwer et al., 2019). Density gradient centrifugation is an improved ultracentrifugation method that produces EVs with higher purity. Although other methods such as serial washes can improve purity, they are associated with low production, risk of structural damage, and contamination (Webber and Clayton, 2013). Therefore, ultracentrifugation may not be an optimal method for therapeutic applications.

Size-based isolation methods include ultrafiltration, size exclusion chromatography, and tangential flow filtration (Li et al., 2017; Willis et al., 2017; Wu et al., 2021b). These methods can produce EVs with comparable or superior purity and/or functional activity to those produced by conventional methods (Busatto et al., 2018; Ludwig et al., 2018); however, pore clogging may occur during the filtration process, resulting in low yield.

Polymer precipitation with polyethylene glycol (PEG) or other polymers could be an effective way to achieve “salting out” of EVs to aggregate (Doyle and Wang, 2019). In clinical applications, PEG or other polymers are considered as contaminants that need to be removed (Doyle and Wang, 2019). Immunoaffinity capture technology, in which antigens are bound to antibodies on the surface of EVs, allows isolation of specific EVs with certain surface proteins.

With the development of the EV research field, various novel strategies have been developed to isolate EVs. However, as there are no standard evaluation metrics for MSC-EV preparation, and no proprietary matrices have been specified, it is difficult to assess the clinical usability of the resulting EVs, as well as the safety of the ingredients used in these EV-harvesting strategies (Reiner et al., 2017).

According to the Minimal Information for Studies of EVs (MISEV) guidelines, the characterization of isolated EVs needs to address morphology, particle size, and surface biomarkers (Théry et al., 2018). The morphology of EVs is observed by scanning electron microscopy, transmission electron microscopy (Théry et al., 2018), electron cryo-microscopy, and atomic force microscopy (Wu et al., 2021b). The size distribution and concentration of EVs are usually determined by nanoparticle tracking analysis, dynamic light scattering, and tunable resistive pulse sensing (An et al., 2021). Common biochemical analysis methods for EVs include western blotting, flow cytometry, and liquid chromatography with mass spectrometry. As the size ranges of exosomes and microvesicles may overlap, these two subtypes cannot be differentiated by size alone.

According to minimal criteria for MSCs suggested by the International Society for Cell and Gene Therapy (ISCT), surface antigens may be the most detectable characteristics that can be transferred to EVs (Dominici et al., 2006). MSC-EVs could be identified based on recently reported MSC-specific surface antigens including CD73, CD90, and CD105, and by the absence of CD14, CD34, and CD11b by Western blot or ELISA (Witwer et al., 2019). The proteomic and lipidomic signatures of MSC-exosomes samples can also be utilized for the identification, characterization, and verification of MSC-exosomes. Previous research revealed that the origin of EV subtypes can be defined by identifying the specific binding affinity, such as cholera toxin B chain (CTB), annexin V (AV), and Shiga toxin B chain (ST) on lipid membrane (Lai and Lim, 2019). And the signature analysis of a specific set of proteins might help in quality control of the preparation and standardization of MSC-exosomes (van Balkom et al., 2019).

4 MSC-exosomes in skin regenerative medicine

MSCs that secrete effectors can be loaded into EVs, thus enabling them to exert bioactive effects (Fu et al., 2019). Exosomes are thought to be the critical bioactive EVs responsible for the paracrine effects of MSCs (Joo et al., 2020), which can be secreted from all types of cells in the human body. According to high-throughput exosome studies, exosomes consist of and carry a diverse load of proteins (Toh et al., 2018), lipids (Davidson et al., 2022), metabolites, RNAs (Fan et al., 2018; Zhang et al., 2019b). Almost 350,000 proteins and more than 27,000 mRNAs and 10,000 miRNAs have so far been detected in exosomes, based on data from Vesiclepedia (http://microvesicles.org/, accessed on 1 August 2022).

There is a growing recognition that MSC-derived exosomes are the initial mediators of the therapeutic efficacy of MSCs, maintaining the biological activity and therapeutic effects of progenitor MSCs (Yeo et al., 2013; Brennan et al., 2017; Ramasubramanian et al., 2019; Yin et al., 2019). The mechanisms underlying the therapeutic potential of MSC-exosomes involve transmission of intercellular information through direct binding to surface ligands via ligand–receptor interactions (Chen et al., 2018; Theodoraki et al., 2018; Yang et al., 2018) or transfer of genetic information and proteins into acceptor cells through cellular internalization or membrane fusion (Skog et al., 2008; Möller and Lobb, 2020) to alter the biological properties of target cells. Research indicates that luminal vehicles within exosomes are absorbed by recipient cells by three methods: direct membrane fusion (Duan et al., 2021), endocytosis (Gurung et al., 2021), and receptor–ligand interactions (Salunkhe et al., 2020).

MSC exosome-based therapies are thought to circumvent the hurdles faced by MSC-based therapies. The main advantages of MSC-exosomes can be summarized as follows. First, the isolation, concentration, storage, and therapeutic dosage of exosomes are more controllable (Witwer et al., 2013). Second, the phospholipid bilayer structure can merge directly with target cells, releasing functional cargos in the receiving cells. Third, exosome-based therapies can avoid the risks of immune rejection and tumorigenesis (Tan et al., 2021). Therefore, MSC-exosomes, as a promising cell-free therapy, exhibit high potential in wound healing and skin regeneration.

4.1 Therapeutic potential of MSC-exosomes in skin tissue regeneration

The pathology of wound healing is regulated by a well-orchestrated processed including inflammation, re-epithelialization, reformation, angiogenesis, and collagen remodeling (Singer and Clark, 1999). MSC-exosomes are believed to have equivalent biological effects to MSCs in tissue regeneration, homeostasis, and wound healing (Yeo et al., 2013; Ramasubramanian et al., 2019; He et al., 2022; Luo et al., 2022; Yan et al., 2022). They can exert their effects on receptor cells by modifying gene expression and protein production. Research efforts have been undertaken to develop MSC-exosomes as therapies in wound healing.

Several studies have examined the effects of MSC-exosomes on the prolonged inflammatory phase in chronic wounds. Anti-inflammatory M2 macrophages have essential roles in promoting cell proliferation and tissue regeneration (Singer and Clark, 1999; Das et al., 2015; Guo et al., 2018). He et al. revealed that bone marrow MSC (BMMSC)-derived exosomes could modulate M2 polarization to promote cutaneous wound healing (He et al., 2019). Adipose tissue-derived stem cell (ADSC)-exosomes have been proven to attenuate macrophage infiltration and reactive oxygen species production (Xu et al., 2020).

Several studies have reported that MSC-exosomes contribute to wound healing with an emphasis on proliferation. Angiogenesis and re-epithelization are important tasks during the proliferation phase of wound healing (Tonnesen et al., 2000; Sorrell et al., 2009). ADSC-exosomes have been reported to promote the proliferation and migration of vascular endothelial cells and sprouting of vascular endothelial tip cells, and to rejuvenate senescent endothelial cells in vivo and in vitro. Ren et al. reported that the angiogenesis induced by ADSC-exosomes in human umbilical vein endothelial cells was associated with the upregulation of platelet-derived growth factors, VEGFA, EGF, and FGF via AKT and ERK signaling pathways (Ren et al., 2019). In a mouse model of a full-thickness skin defect, exosomes from fetal dermal MSCs could accelerate wound healing by activating Notch signaling (Wang et al., 2019a). In an ischemic disease model, miRNA-31 in ADSC-exosomes targeted factor inhibiting HIF-1 (FIH-1) in recipient cells to promote angiogenesis (Zhao et al., 2017; Bian et al., 2019). In addition, preclinical studies in mouse injury models have shown that BMMSC-exosomes accelerate wound healing by promoting collagen synthesis and angiogenesis (El-Tookhy et al., 2017; He et al., 2019).

Human-induced pluripotent stem cells can be generated from a variety of adult cell types after genetic modification. Exosomes from induced pluripotent stem cells (hiPSC)-MSCs can accelerate cutaneous wound healing by promoting vascularization and fibroblast proliferation in rats. After an injury, wounds treated with hiPSC-MSC-exosomes showed improved re-epithelialization and formation of skin appendices, including sebaceous glands and hair follicles. Increasing expression of CD-31 and α-SMA indicates proliferation of endothelial cells and smooth muscle cells that are closely related to vascularization (Zhang et al., 2015). Notably, hiPSC-MSC-exosomes were also found to enhance collagen synthesis and fibroblast proliferation in a dose-dependent manner of human umbilical vein endothelial cells in vitro. The proliferation of human keratinocytes (HaCaT cells) and human dermal fibroblasts was also found to increase significantly after treatment with hiPSC-MSC-exosomes (Kim et al., 2018).

MSC-derived exosomes also have prominent regenerative effects on collagen deposition and can reduce scar deposition. Data suggest that exosomes from human ADSCs can promote fibroblast proliferation and migration through the PI3K/Akt signaling pathways following subcutaneous injection of umbilical cord blood (UCB)-exosomes at full-thickness cutaneous wounds on the backs of mice (Zhang et al., 2018). Another study confirmed the beneficial effects of exosomes from human umbilical cord blood plasma (hUC-MSCs) on wound healing. Levels of collagen I, collagen III, and α-SMA were downregulated after treatment with hUC-MSC-derived exosomes, and expression of myofibroblast-related protein was decreased. In addition, hUC-MSCs have been found to inhibit the activation of the TGF-β1/Smad2/3 signaling pathway. These data indicate that hUC-MSC-derived exosomes could inhibit the transition of fibroblasts to myofibroblasts (Hu et al., 2020).

However, exosome therapeutics for wound healing still face challenges regarding their clinical applications, including poor targeting, a rapid clearance rate, and a relatively short half-life in the complex microenvironment of the wound (Liu et al., 2017). Quantitative analysis of exosome-internalized skin cells show a time-dependent decrease 24 h after injection (Hu et al., 2018). Furthermore, the functions of these cells may have been compromised by the time-consuming harvesting and passage processes and the low survival rate. For these reasons, tissue engineering technology has been introduced to modify the therapeutic potential of natural exosomes, enabling the design of exosomes higher stability and greater therapeutic capability in accelerating wound healing and skin regeneration.

4.2 Challenges in the development of MSC-exosomes-based therapies

Although several preclinical studies have shown promising result, some challenges still hinder the development of exosome-based treatments (Liu et al., 2017; Hu et al., 2018). In clinical settings, the drawbacks of exosome-based therapy may outweigh the advantages. Challenges in achieving a therapeutic effect in clinical settings are found throughout the whole process of MSC-exosome preparation.

To date, various studies are evaluating the biodistribution of exosomes obtained from different sources and used for treatment in several disease models. The underlying mechanism of action (MoA) of MSC-exosomes in each stage of wound healing needs further elucidating. To achieve the therapeutic effect, MSC-exosomes need to present on the target site in a spatiotemporal manner. However, no specific markers are yet available to specifically label and track the biodistribution of MSC-exosomes (He et al., 2019). Moreover, to elucidate the MoA of the therapeutic MSC-exosomes is often implemented by gene editing of the donor MSCs to down-regulated the candidate RNAs or proteins of MSC-exosomes, which may eventually lead to major alterations of MSC-exosomes products (Théry et al., 2018).

The variability of parental MSC sources, the processes for isolation, purification, and identification of exosomes, and the need for a standardized definition of MSC-exosomes need to be addressed (Witwer et al., 2019). In addition, the therapeutic efficacy of MSC-exosomes may be affected by local conditions, the delivery route, and the time window for intervention. For clinical applications of MSC-exosomes, xenogenic components should be avoided during the preparation process. Non-MSC-exosomes derived from the culture media may exist (Witwer et al., 2019).

After administration, the biological effects of MSC-exosomes should be elicited only after they have been engulfed by the target cells. Otherwise, MSC-exosomes would be depleted by immune cells in the circulation. Exosomes are often administered intravenously, subcutaneously, or intraperitoneally (Figure 1). There are also drawbacks also associated with the administration of the exosomes. Systemic administration of exosomes may cause an instant inflammatory reaction and rapid clearance from the blood circulation, resulting in insufficient residence time and homing. The half-life of local administration of exosomes may be even shorter with low bioavailability owing to flushing by body fluid, resulting in a short retention rate of exosomes (Agrahari et al., 2016; Riau et al., 2019). Moreover, therapeutic efficacy may differ between exosomes harvested from in vitro MSC culture and exosomes secreted by MSCs after administration in vivo.

FIGURE 1

5 Bioengineering modified MSC-exosomes

To solve the problems of low effective concentration and limited therapeutic effect, researchers have introduced bioengineering methods into exosome-based therapy. This has resulted in the design of highly specialized bioengineering-modified MSC-exosomes. The features of modified MSC-exosomes are as follows: targeted binding to a specific cell type or tissue; the capacity for loading molecules, drugs, proteins, or genetic information into exosomes or on their surface; and enrichment of an endogenous molecule in the lumen of exosomes or on their surface (Kojima et al., 2018). Current bioengineering methods fall into two main categories: parental MSC-based exosome engineering and direct MSC-exosome engineering (Figure 1A). Several studies have shown the therapeutical roles of bioengineered MSC-exosomes in tissue regeneration and the treatment of CNS disease and cancer (Figure 2) (Haney et al., 2015; Samadikuchaksaraei et al., 2016; Togliatto et al., 2016; Gilligan and Dwyer, 2017; Tao et al., 2017; Yuan et al., 2017; Li et al., 2018b; Liao et al., 2018; Luo et al., 2019; Mathew et al., 2019; Sisa et al., 2019; Kaminski et al., 2020; Xuan et al., 2020; Nuzzi et al., 2021; Sandonà et al., 2021; Yao et al., 2021; Dong et al., 2022; Kurniawati et al., 2022; Miyasaki et al., 2022; Thomas et al., 2022; Rong et al., 2023).

FIGURE 2

5.1 Parental MSC-based exosome engineering

The genetic engineering of parental MSCs produces specific exosomes loaded with functional surface display molecules to specificically label MSC-exosomes or increase exosome accumulation. The most common procedure for encapsulating a protein at the surface of exosomes is the use of an exosome signal peptide such as lysosome-associated membrane protein 2b (LAMP2b) (Alvarez-Erviti et al., 2011). The LAMP2b membrane protein combined with a neuron-targeted short peptide of rabies virus glycoprotein (RVG) is expressed. RVG displayed on the surface may lead to the accumulation of exosomes and enhance exosome delivery (Alvarez-Erviti et al., 2011; Barile and Vassalli, 2017). Vesicular stomatitis virus glycoprotein is an exosome-anchored transmembrane protein containing ectoplasmic, transmembrane helix, and cytoplasmic domains (Meyer et al., 2017). Specific proteins can replace the ectoplasmic and cytoplasmic domains without altering the structures of the exosome membrane. Other documented exosome surface proteins include tetraspanins (CD63, CD9, CD81) (Mathieu et al., 2021; Shi et al., 2021), glycosylphosphatidylinositol (GPI)-anchored cadherin (Nakamura et al., 2020), platelet-derived growth factor receptors (Ohno et al., 2013), and lactadherin (C1C2 domain) (Tian et al., 2021), which could be used for similar purposes.

The EXOtic device can be used to carry mRNAs into parental MSCs to improve exosome production, deliver mRNAs into recipient cells, and promote cell-to-cell communication (Kojima et al., 2018). CRISPR/Cas9 technologies are employed for in vivo gene editing. For example, CRISPR/Cas9 has been used to knock down specific gene sequences in human umbilical MSCs to enhance therapeutic effects (Shao et al., 2020). Such strategies have great potential for gene manipulation in exosome-based therapy and are awaiting further investigation. Transfection has been used to incorporate small RNAs and endogenous molecules into exosomes via loading into parental MSCs. Parental MSCs co-transfected with plasmids encoding production enhancement genes may increase exosome production by 15- to 40-fold as determined by measuring a luminescent reporter (Kojima et al., 2018).

Genetic modification of parental MSCs seems feasible for improving protein surface display, increasing yield of exosomes, loading specific mRNAs into the exosomes, and increasing exosome uptake by recipient cells without any alteration in exosome structures. However, alteration of genetic information may not be suitable for use in exosomes for clinical applications.

5.2 Direct MSC-exosome engineering

Direct exogenous loading approaches after exosome isolation include co-incubation, electroporation, and sonication; other methods such as freeze-thaw and extrusion are rarely used (Figure 1).

Co-incubation is a frequently used strategy to maintain the integrity of the exosome membrane and is especially suitable for loading of hydrophobic molecules such as drugs and RNAs (Xiao et al., 2022; Zhuang et al., 2022). Electroporation is a promising strategy for loading small-molecule drugs or nucleotides into exosomes by creating small-transit pores on the phospholipid bilayer (Lv et al., 2020; Xiong et al., 2022). The membrane gap is automatically restored without altering the morphology of the exosomes. Given that large compounds cannot easily be encapsulated in exosomes, the electroporation approach is particularly suitable for loading nucleotides (Luan et al., 2017). Sonication is also a popular method for exosome engineering (Haney et al., 2015). Exogenous cargo diffuses into the exosomes by passing through the membrane breaks caused by a probe’s mechanical force. Although the loading efficiency of the sonication method is higher than those of co-incubation and electroporation, this approach has some important shortcomings. For instance, the high power of sonication may cause irreversible deformation of exosomes and may disrupt the integrity of exosomes (Haney et al., 2015; Luan et al., 2017).

Extrusion can be used to load exogenous cargos such as gold nanoparticles into exosomes (Khongkow et al., 2019; Van Deun et al., 2020). Freeze–thaw methods have been used to load water-soluble molecules into exosomes by forming ice crystals within lipid membranes that temporarily break the integrity of the exosome membrane (Haney et al., 2015; Hajipour et al., 2021). According to a previous study, extrusion and freeze-thaw methods have notable drawbacks, including low efficiency, low throughput, and the risk of altering the membrane stability of exosomes, resulting in unpredictable side effects (Fuhrmann et al., 2015; Haney et al., 2015; Van Deun et al., 2020). Therefore, such methods are not conventionally used for loading cargo into exosomes.

Exosomes can be modified by using chemical engineering strategies such as click chemistry and metabolic glycoengineering to conjugate ligands to the exosome surface, enabling regulation of the directional migration and targeting of exosomes (You et al., 2021). The advantage of this method is that the highly effective reaction can maintain the size of exosomes without any undesirable side reaction related to the association between exosomes and recipient cells (Smyth et al., 2014; Yoon et al., 2017).

Engineered hybrid exosomes are emerging as an alternative strategy for encapsulating and transferring large nucleic acids such as DNA to target cells and organs and exert therapeutic effects (Lin et al., 2018). Fusing exosomes with synthetic liposomes modifies and tunes the exosome interface to decrease immunogenicity, increase colloidal stability, and improve the half-life in circulation (Lin et al., 2018). Composite carriers enable the efficiency of drug loading to be improved while retaining the function of exosomes. However, there have been few comprehensive evaluations of hybrid exosomes. Hybrid exosomes have been reported to show cytotoxicity slightly greater than that of pure exosomes, as demonstrated by their effects on cell proliferation, which was attributed to the conjugation of the nanoparticles (Chen et al., 2020). As the incubation time or the concentration of hybrid exosomes increased, the viability of progenitor cells decreased.

In summary, various therapeutic molecules and nanoparticles can be efficiently transferred to exosomes using the abovementioned modification procedures. However, these methods require repeated purification and centrifugation using detergents, enzymes or other methods, which might disrupt the integrity of exosomes or reduce bioactivity (Levy et al., 2022). Therefore, novel bioengineering procedures are needed to compensate for these limitations.

5.3 Co-administration with hydrogels

Deepening understanding of exosome-based therapies has spurred research combining biomaterials to formulate sustained-release therapeutic systems. Improving the ability of MSC-exosomes to accelerate wound healing is the driving force behind the research integrating biomaterials and bioengineering. Ideal biomaterials can be used to maximize the therapeutic functions of exosomes as wound dressings or scaffolds by increasing their durability and stability.

A variety of biomaterials, including membranes, electrospun nanofibers, colloidal nanoparticles, and hydrogels, have been used to facilitate the controlled release of bioactive molecules for skin regeneration (Liang et al., 2019; Bai et al., 2022; Hu et al., 2022). Among them, hydrogels have recently attracted attention for applications as delivery systems and scaffold dressings with multifunctional properties such as antibacterial activity, hemostatic ability, tissue adhesion, anti-ultraviolet activity, injectability, and self-healing (Lokhande et al., 2018; Safari et al., 2022). Hydrogels can mimic natural extracellular matrix (ECM) and provide a three-dimensional framework to support growth and proliferation of loaded cells and regulate biomolecule activation (Riha et al., 2021). Moreover, three-dimensional hydrophilic polymer networks can maintain moisture at the wound site.

The combination of hydrogels and exosomes plays a crucial part in adjusting the wound inflammation microenvironment, promoting vascularization, enhancing re-epithelialization, and accelerating wound healing (Qian et al., 2020; Zhang et al., 2021a; Kudinov et al., 2021; Geng et al., 2022). Furthermore, a comparative study has demonstrated a synergistic effect of hydrogel–exosome complexes compared with exosome therapy alone (Zhou et al., 2022).

In summary, although several studies have shown great potential for MSC-exosomes in clinical applications, many unresolved issues still limit their practical use. Before exosomes are introduced into clinical settings, safety concerns, cytotoxicity, and reproducibility of production need to be solved (Luan et al., 2017; Murphy et al., 2019). The development of bioengineering methodologies for exosome-based therapy could provide a means of bridging the gap.

6 Applications of bioengineering-modified MSC-derived exosomes in skin wound healing and regeneration

In this section, we review the therapeutic applications of modified MSC-exosomes in wound healing and skin regeneration and the improvements in regenerative efficiency that have been achieved compared with MSC-derived exosomes. As mentioned in the previous discussion on modified exosomes and bioengineering technology, there are two current trends for implementing modified MSC-exosomes in wound healing and skin regeneration.

6.1 Bioengineering the properties of MSC-exosomes

One solution is to bioengineer the properties of exosomes, such as their cargos or surface molecular functions, before administration (Table 1).

The RNA cargo of MSC exosomes is considered a pivotal factor in eliciting biological functions to target cells and has raised great attention. Previous mechanistic studies have shown that exosome-derived RNAs play a crucial role in immunomodulatory capacity (He et al., 2019; Zhao et al., 2021; Wang et al., 2022), stimulate the differentiation of fibroblasts, keratinocytes, and endothelial cells, promote angiogenesis (Liang et al., 2016), and prohibit tissue hyperplasia and scar formation (Fang et al., 2016). Such abilities can be enhanced after bioengineering modification. For example, modified exosomes derived from bone marrow MSCs (BMMSCs) enriched with miRNA-542-3p could enhance proliferation, migration, and angiogenesis of human skin fibroblasts/human dermal microvascular endothelial cells in vitro and in vivo (Xiong et al., 2022). The potential therapeutic value of exosomes loaded with circular RNAs has been studied in full-thickness skin wound repair in diabetic rats. The MSC-exosomes enriched with mmu_circ_0000250 could efficiently regulate miR-128-3p and the expression of SIRT1 to control inflammation (Shi et al., 2020b). Another study modified MSCs to generate exosomes enriched for long ncRNA H19, leading to the regulation of the PI3K/AKT signaling pathway and suppression of inflammatory responses and apoptosis in a diabetic foot ulcer mouse model (Li et al., 2020). Nanoparticles can be loaded into the exosomes to promote angiogenesis. BMSCs-exosomes loaded with magnetic Fe₃O₄ nanoparticles, with upregulation of exosome miR-1260a, were confirmed to enhance angiogenesis (Wu et al., 2021a).

Deep sequencing of MSC exosomal RNA revealed that MSC excretes exosomal miRNAs in a selective manner, many of which are precursor miRNAs incapable of protein-coding (Chen et al., 2010; Pritchard et al., 2012). In addition, a prerequisite for RNA-based MoA is that the exosome-derived miRNAs reach a therapeutic dose. However, the amount of miRNAs in standard preparation is approximately 60 ng per 100 μg exosome. Leaving aside the fact that the distribution of a specific miRNA in an exosome is about 1:100 (Chevillet et al., 2014; Albanese et al., 2021). According to the analysis of Toh WS et al., MSC-exosome-derived miRNAs are unable to achieve the therapeutic effect as their low concentration in single exosome, immature status, and the absence of RNA-induced silencing complex (RISC) (Toh et al., 2018).

The protein-mediated mechanism of MSC-exosomes in wound healing has raised attention (Sung et al., 2019; Bari et al., 2020; Kudinov et al., 2021; Camões et al., 2022; Zhang et al., 2022). Comprehensive proteomic analysis showed that the proteins TGF-β, ITGA1-3/5, IL-6, CDC151, S100A10, and Wnt5α, as being enriched in MSC-exosomes in 3D culture, were confirmed to be associated with wound healing (Camões et al., 2022). In infected burn injury, PGE2, IL-6, IL-8, or IFN-γ, IL-10, growth factors, and chemokines secreted by placental MSC secretome were found to accelerate dermal fibroblast and keratinocyte migration and proliferation, stimulate angiogenesis, and reduce scarring (Kudinov et al., 2021). Angiogenic protein cargos, including angiogenin, angiopoietin-1, HGF, and vascular endothelial growth factor (VEGF) in thrombin preconditioning MSC-exosomes were enhanced compared with that of naïve MSC-exosomes, thus boosting angiogenesis (Sung et al., 2019). As with RNA-based MoA, the proteins should be in therapeutic doses to elicit their therapeutic effect.

6.2 Hydrogel encapsulation of MSC-exosomes

Another bioengineering strategy combines exosomes and hydrogels to exert synergistic functions after administration (Table 2) (Wang et al., 2019b). Hydrogels act as three-dimensional porous scaffolds to provide a favorable environment for cell proliferation and ECM remodeling (Yang et al., 2020). A complex of exosomes and hydrogels can also act as a sustainable release system for an extended period and exert lasting curative functions. The flexible morphology of biomaterials enables the construction of more variable forms of exosomes (Wang et al., 2019c).

MSC-exosomes encapsulated by biomaterials could avoid being rapidly released into the bloodstream and exert their therapeutic effect in a dose-dependent manner at designated sites. Hydrogels can be used as loading vehicles to enhance exosome retention rates and achieve synergistic therapeutic efficacy (Wang et al., 2019b; Das et al., 2022). A thermoactivated polymer has been shown to enable sustained administration of exosomes, maintaining 65% of the initial number of exosomes after 25 days (Das et al., 2022). This study also found no cytotoxic effects on cells in contact with the hydrogels or when cells were embedded in the hydrogel constructs. Surface modification with nanoparticles increases the production of exosomes. Bioavailable nanoparticles based on iron oxide with poly(lactic-co-glycolic acid) were designed to improve the yield of exosomes by stimulating MVB formation (Park et al., 2020).

Biomaterials may also combine engineered exosomes to improve the therapeutic efficiency of exosomes in wound healing (Table 3). As three-dimensional porous scaffolds, hydrogels provide exosomes with a favorable environment that promotes cell proliferation and ECM remodeling and have thus gained more research attention. Furthermore, the transformation of biomaterials provides a greater scope for applications of exosomes (Wang et al., 2019c; Yang et al., 2020). An in vivo study showed that incorporating gingival-MSC-derived exosomes into a chitosan/silk-based hydrogel sponge could facilitate wound healing by promoting re-epithelialization, angiogenesis, and neuronal ingrowth, as well as collagen remodeling (Shi et al., 2017). In a study by Wang et al., an injectable methylcellulose-chitosan hydrogel loaded with exosomes derived from human placental MSCs was constructed to synergistically promote angiogenesis and inhibit apoptosis (Wang et al., 2019b). The modified exosome hydrogel complex forms a suitable injectable wound dressing with appropriate gelation time, mechanical properties, and high self-healing efficiency. In a diabetic wound-infected model, BMSC-exosomes were loaded in an antibacterial hydrogel and enabled the wound inflammation microenvironment to be adjusted, as well as promoting neovascularization and accelerating wound healing (Geng et al., 2022).

6.3 Clinical trials of MSC-EVs for wound healing and skin regeneration

Overall, bioengineering technologies have been implemented in exosome-based therapy to make MSC-derived exosomes more effective in treating chronic wounds. Previous valuable research findings have expanded the scope of applications of exosomes in treatment of cutaneous wounds and established a theoretical basis for clinical trials of bioengineered MSC- exosomes.

7 Prospects and conclusion

Skin wound healing is a complex multi-stage biological process. Chronic wounds characterized by poor vascularization and prolonged inflammation still threaten patients’ health and quality of life. Traditional treatments for skin damage are time-consuming and costly, and existing therapies have little therapeutic effect in promoting chronic wound healing. Therefore, new therapeutic options are needed.

Over the past decades, therapies based on MSCs with multi-lineage potential have shown impressive therapeutic efficacy in regenerative medicine (Pittenger et al., 1999). However, significant challenges regarding immunocompatibility, stability, migration capacity, and pluripotent development still need to be addressed (Jiang et al., 2002). Current opinion is that MSCs exert their therapeutic effects mainly via their paracrine activity, mostly through the release of EVs (Herrera et al., 2010; Lai et al., 2010; Lener et al., 2015). As the main bioactive factor of the MSC secretome, MSC-exosomes are reported to have similar therapeutic effects to MSCs that transfer genetic information or biologically active molecules into target cells (Zhang et al., 2014).

In light of these properties, considerable research efforts have been put into MSC-exosomes therapies. In preclinical models, MSC-exosomes have been shown to have several advantages compared with MSCs, including minimal immune rejection and tumorigenesis risk (Zhang et al., 2014) and no side effects in vivo (Kordelas et al., 2014). However, before translation of MSC-exosome-based therapeutics into clinical settings, several issues need to be addressed.

The challenges include the manufacturing process of MSC-exosomes, such as characterization, isolation, purification, clinical safety of donor cells and recipient cells, and the manufacturing process. In addition, quality control hinders the translation of MSC-exosome-based therapies into clinical applications.

Microvesicles and exosomes have some common characteristics; for instance, they both have a bilateral phospholipid membranous structure and contain specific proteins, lipid, as well as RNAs, and their size ranges overlap; thus, current isolation procedures cannot discriminate different EV subtypes (Gould and Raposo, 2013; Giebel et al., 2017). Moreover, different manufacturing processes and apparently homogenous EV-releasing MSCs can result in different EV subtypes (Börger et al., 2017).

Currently, the definition of MSC-exosomes is based on the ISCT minimal criteria and the MISEV recommendations (Dominici et al., 2006; Théry et al., 2018). However, both of these sources of guidance are insufficient to distinguish MSC-exosomes from non-MSC-exosomes, and there is no process for functional assessment of MSC-exosomes. Therefore, in this review, the term “MSC-exosome” was used to describe exosome-containing products derived from MSCs. Another challenge during the application of MSC-exosomes in clinical studies is the lack of a standardized manufacturing process to produce the final product. Quality tests for batch size, purity, potency, reproducibility, safety, and storage stability of the MSC-exosome products need to be established. Currently, there is no optimal isolation method to achieve high purity without compromising the integrity, yield, or functionality of the product (Reiner et al., 2017). Finally, storage and transport conditions of MSC-exosome products must also be addressed. Recently, several studies on the storage conditions and biological activity of the native and cargo-loading MSC-exosomes have carried out the ideal storage conditions (Levy et al., 2022). These results may suggest that lyophilization and storage at room temperature can preserve the enhanced bioactivity of cargo-loading exosomes. In this case, additional steps are required to verify the producibility of the MSC-exosomes as a clinical product.

With advances in engineering and biotechnology (Alvarez-Erviti et al., 2011; Haney et al., 2015; You et al., 2021; Xiao et al., 2022; Zhuang et al., 2022), MSC-exosomes produced under given conditions may mitigate some of the shortcomings of natural MSC-exosomes mentioned above. MSC-exosomes, as natural carriers of genetic information and proteins, can potentially be modified as targeted therapeutic delivery systems by genetic editing of parental MSCs (Alvarez-Erviti et al., 2011) or by direct modification of MSC-exosomes (Haney et al., 2015; You et al., 2021; Xiao et al., 2022; Zhuang et al., 2022). Comparing with synthetic nanoparticles delivery system, EVs delivery RNA and protein cargos to cells shown higher efficacy (Murphy et al., 2021). However, the underlying MoA, feasibility, efficiency and producibility of engineering MSC-exosomes products need to be confirmed.

Taken together, the studies reviewed here suggest that MSC-exosomes could provide an alternative option for wound healing. However, more research is required to make modified MSC-exosomes more widely available and suitable for clinical applications in wound healing and skin regeneration.

References

• 1

  AgrahariV.MandalA.AgrahariV.TrinhH. M.JosephM.RayA.et al (2016). A comprehensive insight on ocular pharmacokinetics. Drug Deliv. Transl. Res.6 (6), 735–754. 10.1007/s13346-016-0339-2

  • CrossRef
  • Google Scholar

• 2

  AlbaneseM.ChenY. A.HülsC.GärtnerK.TagawaT.Mejias-PerezE.et al (2021). MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. PLoS Genet.17 (12), e1009951. 10.1371/journal.pgen.1009951

  • CrossRef
  • Google Scholar

• 3

  Alvarez-ErvitiL.SeowY.YinH.BettsC.LakhalS.WoodM. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol.29 (4), 341–345. 10.1038/nbt.1807

  • CrossRef
  • Google Scholar

• 4

  AnY.LinS.TanX.ZhuS.NieF.ZhenY.et al (2021). Exosomes from adipose-derived stem cells and application to skin wound healing. Cell Prolif.54 (3), e12993. 10.1111/cpr.12993

  • CrossRef
  • Google Scholar

• 5

  BaiL.LiuL.EsquivelM.TardyB. L.HuanS.NiuX.et al (2022). Nanochitin: Chemistry, structure, assembly, and applications. Chem. Rev.122 (13), 11604–11674. 10.1021/acs.chemrev.2c00125

  • CrossRef
  • Google Scholar

• 6

  BariE.Di SilvestreD.MastracciL.GrilloF.GrisoliP.MarrubiniG.et al (2020). GMP-compliant sponge-like dressing containing MSC lyo-secretome: Proteomic network of healing in a murine wound model. Eur. J. Pharm. Biopharm.155, 37–48. 10.1016/j.ejpb.2020.08.003

  • CrossRef
  • Google Scholar

• 7

  BarileL.VassalliG. (2017). Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol. Ther.174, 63–78. 10.1016/j.pharmthera.2017.02.020

  • CrossRef
  • Google Scholar

• 8

  BianX.MaK.ZhangC.FuX. (2019). Therapeutic angiogenesis using stem cell-derived extracellular vesicles: An emerging approach for treatment of ischemic diseases. Stem Cell Res. Ther.10 (1), 158. 10.1186/s13287-019-1276-z

  • CrossRef
  • Google Scholar

• 9

  BörgerV.BremerM.Ferrer-TurR.GockelnL.StambouliO.BecicA.et al (2017). Mesenchymal stem/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents. Int. J. Mol. Sci.18 (7), 1450. 10.3390/ijms18071450

  • CrossRef
  • Google Scholar

• 10

  BornL. J.ChangK. H.ShoureshiP.LayF.BengaliS.HsuA. T. W.et al (2022). HOTAIR-loaded mesenchymal stem/stromal cell extracellular vesicles enhance angiogenesis and wound healing. Adv. Healthc. Mater11 (5), e2002070. 10.1002/adhm.202002070

  • CrossRef
  • Google Scholar

• 11

  BrennanM. A.RenaudA.GuillotonF.MebarkiM.TrichetV.SensebéL.et al (2017). Inferior in vivo osteogenesis and superior angiogenesis of human adipose-derived stem cells compared with bone marrow-derived stem cells cultured in xeno-free conditions. Stem Cells Transl. Med.6 (12), 2160–2172. 10.1002/sctm.17-0133

  • CrossRef
  • Google Scholar

• 12

  BusattoS.VilanilamG.TicerT.LinW. L.DicksonD. W.ShapiroS.et al (2018). Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells7 (12), 273. 10.3390/cells7120273

  • CrossRef
  • Google Scholar

• 13

  CamõesS. P.BulutO.YazarV.GasparM. M.SimõesS.FerreiraR.et al (2022). 3D-MSCs A151 ODN-loaded exosomes are immunomodulatory and reveal a proteomic cargo that sustains wound resolution. J. Adv. Res.41, 113–128. 10.1016/j.jare.2022.01.013

  • CrossRef
  • Google Scholar

• 14

  Casado-DíazA.Quesada-GómezJ. M.DoradoG. (2020). Extracellular vesicles derived from mesenchymal stem cells (MSC) in regenerative medicine: Applications in skin wound healing. Front. Bioeng. Biotechnol.8, 146. 10.3389/fbioe.2020.00146

  • CrossRef
  • Google Scholar

• 15

  CavanaghP. R.LipskyB. A.BradburyA. W.BotekG. (2005). Treatment for diabetic foot ulcers. Lancet366 (9498), 1725–1735. 10.1016/s0140-6736(05)67699-4

  • CrossRef
  • Google Scholar

• 16

  ChachquesJ. C.GardinC.LilaN.FerroniL.MigonneyV.Falentin-DaudreC.et al (2021). Elastomeric cardiowrap scaffolds functionalized with mesenchymal stem cells-derived exosomes induce a positive modulation in the inflammatory and wound healing response of mesenchymal stem cell and macrophage. Biomedicines9 (7), 824. 10.3390/biomedicines9070824

  • CrossRef
  • Google Scholar

• 17

  ChenD.HaoH.FuX.HanW. (2016). Insight into reepithelialization: How do mesenchymal stem cells perform?Stem Cells Int.2016, 6120173. 10.1155/2016/6120173

  • CrossRef
  • Google Scholar

• 18

  ChenG.HuangA. C.ZhangW.ZhangG.WuM.XuW.et al (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature560 (7718), 382–386. 10.1038/s41586-018-0392-8

  • CrossRef
  • Google Scholar

• 19

  ChenH.LuoC.YangM.LiJ.MaP.ZhangX. (2020). Intracellular uptake of and sensing with SERS-active hybrid exosomes: Insight into a role of metal nanoparticles. Nanomedicine (Lond)15 (9), 913–926. 10.2217/nnm-2019-0419

  • CrossRef
  • Google Scholar

• 20

  ChenT. S.LaiR. C.LeeM. M.ChooA. B.LeeC. N.LimS. K. (2010). Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res.38 (1), 215–224. 10.1093/nar/gkp857

  • CrossRef
  • Google Scholar

• 21

  ChevilletJ. R.KangQ.RufI. K.BriggsH. A.VojtechL. N.HughesS. M.et al (2014). Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc. Natl. Acad. Sci. U. S. A.111 (41), 14888–14893. 10.1073/pnas.1408301111

  • CrossRef
  • Google Scholar

• 22

  DasA.NikhilA.KumarA. (2022). Preparation of thermo-responsive polymer encapsulated exosomes and its role as a therapeutic agent for blood clot lysis. Colloids Surf. B Biointerfaces216, 112580. 10.1016/j.colsurfb.2022.112580

  • CrossRef
  • Google Scholar

• 23

  DasA.SinhaM.DattaS.AbasM.ChaffeeS.SenC. K.et al (2015). Monocyte and macrophage plasticity in tissue repair and regeneration. Am. J. Pathol.185 (10), 2596–2606. 10.1016/j.ajpath.2015.06.001

  • CrossRef
  • Google Scholar

• 24

  DavidsonS. M.BoulangerC. M.AikawaE.BadimonL.BarileL.BinderC. J.et al (2022). Methods for the identification and characterization of extracellular vesicles in cardiovascular studies - from exosomes to microvesicles. Cardiovasc Res., cvac031. 10.1093/cvr/cvac031

  • CrossRef
  • Google Scholar

• 25

  DominiciM.Le BlancK.MuellerI.Slaper-CortenbachI.MariniF.KrauseD.et al (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy8 (4), 315–317. 10.1080/14653240600855905

  • CrossRef
  • Google Scholar

• 26

  DonatiG.WattF. M. (2015). Stem cell heterogeneity and plasticity in epithelia. Cell Stem Cell16 (5), 465–476. 10.1016/j.stem.2015.04.014

  • CrossRef
  • Google Scholar

• 27

  DongZ.GuH.GuoQ.LiuX.LiF.LiuH.et al (2022). Circulating small extracellular vesicle-derived miR-342-5p ameliorates beta-amyloid formation via targeting beta-site APP cleaving enzyme 1 in alzheimer's disease. Cells11 (23), 3830. 10.3390/cells11233830

  • CrossRef
  • Google Scholar

• 28

  DoyleL. M.WangM. Z. (2019). Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells8 (7), 727. 10.3390/cells8070727

  • CrossRef
  • Google Scholar

• 29

  DuanL.XuL.XuX.QinZ.ZhouX.XiaoY.et al (2021). Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale13 (3), 1387–1397. 10.1039/d0nr07622h

  • CrossRef
  • Google Scholar

• 30

  El-TookhyO. S.ShamaaA. A.ShehabG. G.AbdallahA. N.AzzamO. M. (2017). Histological evaluation of experimentally induced critical size defect skin wounds using exosomal solution of mesenchymal stem cells derived microvesicles. Int. J. Stem Cells10 (2), 144–153. 10.15283/ijsc17043

  • CrossRef
  • Google Scholar

• 31

  FanQ.YangL.ZhangX.PengX.WeiS.SuD.et al (2018). The emerging role of exosome-derived non-coding RNAs in cancer biology. Cancer Lett.414, 107–115. 10.1016/j.canlet.2017.10.040

  • CrossRef
  • Google Scholar

• 32

  FangJ.WeiY.TengX.ZhaoS.HuaJ. (2018). Immortalization of canine adipose-derived mesenchymal stem cells and their seminiferous tubule transplantation. J. Cell Biochem.119 (4), 3663–3670. 10.1002/jcb.26574

  • CrossRef
  • Google Scholar

• 33

  FangS.XuC.ZhangY.XueC.YangC.BiH.et al (2016). Umbilical cord-derived mesenchymal stem cell-derived exosomal MicroRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-β/SMAD2 pathway during wound healing. Stem Cells Transl. Med.5 (10), 1425–1439. 10.5966/sctm.2015-0367

  • CrossRef
  • Google Scholar

• 34

  FrykbergR. G.BanksJ. (2015). Challenges in the treatment of chronic wounds. Adv. Wound Care (New Rochelle)4 (9), 560–582. 10.1089/wound.2015.0635

  • CrossRef
  • Google Scholar

• 35

  FuX.LiuG.HalimA.JuY.LuoQ.SongA. G. (2019). Mesenchymal stem cell migration and tissue repair. Cells8 (8), 784. 10.3390/cells8080784

  • CrossRef
  • Google Scholar

• 36

  FuhrmannG.SerioA.MazoM.NairR.StevensM. M. (2015). Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J. Control Release205, 35–44. 10.1016/j.jconrel.2014.11.029

  • CrossRef
  • Google Scholar

• 37

  GengX.QiY.LiuX.ShiY.LiH.ZhaoL. (2022). A multifunctional antibacterial and self-healing hydrogel laden with bone marrow mesenchymal stem cell-derived exosomes for accelerating diabetic wound healing. Biomater. Adv.133, 112613. 10.1016/j.msec.2021.112613

  • CrossRef
  • Google Scholar

• 38

  GiebelB.KordelasL.BörgerV. (2017). Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles. Stem Cell Investig.4, 84. 10.21037/sci.2017.09.06

  • CrossRef
  • Google Scholar

• 39

  GilliganK. E.DwyerR. M. (2017). Engineering exosomes for cancer therapy. Int. J. Mol. Sci.18 (6), 1122. 10.3390/ijms18061122

  • CrossRef
  • Google Scholar

• 40

  GimonaM.BrizziM. F.ChooA. B. H.DominiciM.DavidsonS. M.GrillariJ.et al (2021). Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy23 (5), 373–380. 10.1016/j.jcyt.2021.01.001

  • CrossRef
  • Google Scholar

• 41

  GouldS. J.RaposoG. (2013). As we wait: Coping with an imperfect nomenclature for extracellular vesicles. J. Extracell. Vesicles2, 20389. 10.3402/jev.v2i0.20389

  • CrossRef
  • Google Scholar

• 42

  GuoJ.QiuX.ZhangL.WeiR. (2018). Smurf1 regulates macrophage proliferation, apoptosis and migration via JNK and p38 MAPK signaling pathways. Mol. Immunol.97, 20–26. 10.1016/j.molimm.2018.03.005

  • CrossRef
  • Google Scholar

• 43

  GurungS.PerocheauD.TouramanidouL.BaruteauJ. (2021). The exosome journey: From biogenesis to uptake and intracellular signalling. Cell Commun. Signal19 (1), 47. 10.1186/s12964-021-00730-1

  • CrossRef
  • Google Scholar

• 44

  GushikenL. F. S.BeserraF. P.BastosJ. K.JacksonC. J.PellizzonC. H. (2021). Cutaneous wound healing: An update from physiopathology to current therapies. Life (Basel)11 (7), 665. 10.3390/life11070665

  • CrossRef
  • Google Scholar

• 45

  HajipourH.FarzadiL.RoshangarL.LatifiZ.KahrobaH.ShahnaziV.et al (2021). A human chorionic gonadotropin (hCG) delivery platform using engineered uterine exosomes to improve endometrial receptivity. Life Sci.275, 119351. 10.1016/j.lfs.2021.119351

  • CrossRef
  • Google Scholar

• 46

  HaneyM. J.KlyachkoN. L.ZhaoY.GuptaR.PlotnikovaE. G.HeZ.et al (2015). Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control Release207, 18–30. 10.1016/j.jconrel.2015.03.033

  • CrossRef
  • Google Scholar

• 47

  HeX.DongZ.CaoY.WangH.LiuS.LiaoL.et al (2019). MSC-derived exosome promotes M2 polarization and enhances cutaneous wound healing. Stem Cells Int.2019, 7132708. 10.1155/2019/7132708

  • CrossRef
  • Google Scholar

• 48

  HeX.ZhangC.AmirsaadatS.JalilA. T.KadhimM. M.AbasiM.et al (2022). Curcumin-loaded mesenchymal stem cell-derived exosomes efficiently attenuate proliferation and inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Appl. Biochem. Biotechnol.195, 51–67. 10.1007/s12010-022-04090-5

  • CrossRef
  • Google Scholar

• 49

  HerreraM. B.FonsatoV.GattiS.DeregibusM. C.SordiA.CantarellaD.et al (2010). Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. J. Cell Mol. Med.14 (6), 1605–1618. 10.1111/j.1582-4934.2009.00860.x

  • CrossRef
  • Google Scholar

• 50

  HuH.ZhaiX.LiW.JiS.DongW.ChenW.et al (2022). A photo-triggering double cross-linked adhesive, antibacterial, and biocompatible hydrogel for wound healing. iScience25 (7), 104619. 10.1016/j.isci.2022.104619

  • CrossRef
  • Google Scholar

• 51

  HuJ.ChenY.HuangY.SuY. (2020). Human umbilical cord mesenchymal stem cell-derived exosomes suppress dermal fibroblasts-myofibroblats transition via inhibiting the TGF-β1/Smad 2/3 signaling pathway. Exp. Mol. Pathol.115, 104468. 10.1016/j.yexmp.2020.104468

  • CrossRef
  • Google Scholar

• 52

  HuY.RaoS. S.WangZ. X.CaoJ.TanY. J.LuoJ.et al (2018). Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function. Theranostics8 (1), 169–184. 10.7150/thno.21234

  • CrossRef
  • Google Scholar

• 53

  HuangJ.YuM.YinW.LiangB.LiA.LiJ.et al (2021). Development of a novel RNAi therapy: Engineered miR-31 exosomes promoted the healing of diabetic wounds. Bioact. Mater6 (9), 2841–2853. 10.1016/j.bioactmat.2021.02.007

  • CrossRef
  • Google Scholar

• 54

  JiangL.ZhangY.LiuT.WangX.WangH.SongH.et al (2020). Exosomes derived from TSG-6 modified mesenchymal stromal cells attenuate scar formation during wound healing. Biochimie177, 40–49. 10.1016/j.biochi.2020.08.003

  • CrossRef
  • Google Scholar

• 55

  JiangY.JahagirdarB. N.ReinhardtR. L.SchwartzR. E.KeeneC. D.Ortiz-GonzalezX. R.et al (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature418 (6893), 41–49. 10.1038/nature00870

  • CrossRef
  • Google Scholar

• 56

  JohnstoneR. M.AdamM.HammondJ. R.OrrL.TurbideC. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem.262 (19), 9412–9420. 10.1016/s0021-9258(18)48095-7

  • CrossRef
  • Google Scholar

• 57

  JooH. S.SuhJ. H.LeeH. J.BangE. S.LeeJ. M. (2020). Current knowledge and future perspectives on mesenchymal stem cell-derived exosomes as a new therapeutic agent. Int. J. Mol. Sci.21 (3), 727. 10.3390/ijms21030727

  • CrossRef
  • Google Scholar

• 58

  KajimotoT.OkadaT.MiyaS.ZhangL.NakamuraS. (2013). Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of exosomal multivesicular endosomes. Nat. Commun.4, 2712. 10.1038/ncomms3712

  • CrossRef
  • Google Scholar

• 59

  KaminskiN.KösterC.MouloudY.BörgerV.Felderhoff-MüserU.BendixI.et al (2020). Mesenchymal stromal cell-derived extracellular vesicles reduce neuroinflammation, promote neural cell proliferation and improve oligodendrocyte maturation in neonatal hypoxic-ischemic brain injury. Front. Cell Neurosci.14, 601176. 10.3389/fncel.2020.601176

  • CrossRef
  • Google Scholar

• 60

  KhongkowM.YataT.BoonrungsimanS.RuktanonchaiU. R.GrahamD.NamdeeK. (2019). Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood-brain barrier penetration. Sci. Rep.9 (1), 8278. 10.1038/s41598-019-44569-6

  • CrossRef
  • Google Scholar

• 61

  KimH. S.SunX.LeeJ. H.KimH. W.FuX.LeongK. W. (2019). Advanced drug delivery systems and artificial skin grafts for skin wound healing. Adv. Drug Deliv. Rev.146, 209–239. 10.1016/j.addr.2018.12.014

  • CrossRef
  • Google Scholar

• 62

  KimS.LeeS. K.KimH.KimT. M. (2018). Exosomes secreted from induced pluripotent stem cell-derived mesenchymal stem cells accelerate skin cell proliferation. Int. J. Mol. Sci.19 (10), 3119. 10.3390/ijms19103119

  • CrossRef
  • Google Scholar

• 63

  KimParaisoH. T.RebeccaV. W.EthanV. A.Ann ChenY.Cecilia MunkoA.InnaFedorenkoV.et al (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res.71 (7), 2750–2760. 10.1158/0008-5472.CAN-10-2954

  • CrossRef
  • Google Scholar

• 64

  KojimaR.BojarD.RizziG.HamriG. C.El-BabaM. D.SaxenaP.et al (2018). Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment. Nat. Commun.9 (1), 1305. 10.1038/s41467-018-03733-8

  • CrossRef
  • Google Scholar

• 65

  KordelasL.RebmannV.LudwigA. K.RadtkeS.RuesingJ.DoeppnerT. R.et al (2014). MSC-Derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. Leukemia28 (4), 970–973. 10.1038/leu.2014.41

  • CrossRef
  • Google Scholar

• 66

  KudinovV. A.ArtyushevR. I.ZurinaI. M.LapshinR. D.SnopovaL. B.MukhinaI. V.et al (2021). Antimicrobial and regenerative effects of placental multipotent mesenchymal stromal cell secretome-based chitosan gel on infected burns in rats. Pharm. (Basel)14 (12), 1263. 10.3390/ph14121263

  • CrossRef
  • Google Scholar

• 67

  KurniawatiI.LiuM. C.HsiehC. L.DoA. D.SungS. Y. (2022). Targeting castration-resistant prostate cancer using mesenchymal stem cell exosomes for therapeutic MicroRNA-let-7c delivery. Front. Biosci. (Landmark Ed.27 (9), 256. 10.31083/j.fbl2709256

  • CrossRef
  • Google Scholar

• 68

  LaiR. C.ArslanF.LeeM. M.SzeN. S.ChooA.ChenT. S.et al (2010). Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res.4 (3), 214–222. 10.1016/j.scr.2009.12.003

  • CrossRef
  • Google Scholar

• 69

  LaiR. C.LimS. K. (2019). Membrane lipids define small extracellular vesicle subtypes secreted by mesenchymal stromal cells. J. Lipid Res.60 (2), 318–322. 10.1194/jlr.R087411

  • CrossRef
  • Google Scholar

• 70

  LeeM.JeongS. Y.HaJ.KimM.JinH. J.KwonS. J.et al (2014). Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem. Biophys. Res. Commun.446 (4), 983–989. 10.1016/j.bbrc.2014.03.051

  • CrossRef
  • Google Scholar

• 71

  LenerT.GimonaM.AignerL.BörgerV.BuzasE.CamussiG.et al (2015). Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J. Extracell. Vesicles4, 30087. 10.3402/jev.v4.30087

  • CrossRef
  • Google Scholar

• 72

  LevyD.JeyaramA.BornL. J.ChangK. H.AbadchiS. N.HsuA. T. W.et al (2022). Impact of storage conditions and duration on function of native and cargo-loaded mesenchymal stromal cell extracellular vesicles. Cytotherapy. 10.1016/j.jcyt.2022.11.006

  • CrossRef
  • Google Scholar

• 73

  LevyO.KuaiR.SirenE. M. J.BhereD.MiltonY.NissarN.et al (2020). Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv.6 (30), eaba6884. 10.1126/sciadv.aba6884

  • CrossRef
  • Google Scholar

• 74

  LiB.LuanS.ChenJ.ZhouY.WangT.LiZ.et al (2020). The MSC-derived exosomal lncRNA H19 promotes wound healing in diabetic foot ulcers by upregulating PTEN via MicroRNA-152-3p. Mol. Ther. Nucleic Acids19, 814–826. 10.1016/j.omtn.2019.11.034

  • CrossRef
  • Google Scholar

• 75

  LiD.ZhangP.YaoX.LiH.ShenH.LiX.et al (2018). Exosomes derived from miR-133b-modified mesenchymal stem cells promote recovery after spinal cord injury. Front. Neurosci.12, 845. 10.3389/fnins.2018.00845

  • CrossRef
  • Google Scholar

• 76

  LiM.KeQ. F.TaoS. C.GuoS. C.RuiB. Y.GuoY. P. (2016). Fabrication of hydroxyapatite/chitosan composite hydrogels loaded with exosomes derived from miR-126-3p overexpressed synovial mesenchymal stem cells for diabetic chronic wound healing. J. Mater Chem. B4 (42), 6830–6841. 10.1039/c6tb01560c

  • CrossRef
  • Google Scholar

• 77

  LiP.KaslanM.LeeS. H.YaoJ.GaoZ. (2017). Progress in exosome isolation techniques. Theranostics7 (3), 789–804. 10.7150/thno.18133

  • CrossRef
  • Google Scholar

• 78

  LiW.LiuY.ZhangP.TangY.ZhouM.JiangW.et al (2018). Tissue-engineered bone immobilized with human adipose stem cells-derived exosomes promotes bone regeneration. ACS Appl. Mater Interfaces10 (6), 5240–5254. 10.1021/acsami.7b17620

  • CrossRef
  • Google Scholar

• 79

  LiangX.ZhangL.WangS.HanQ.ZhaoR. C. (2016). Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J. Cell Sci.129 (11), 2182–2189. 10.1242/jcs.170373

  • CrossRef
  • Google Scholar

• 80

  LiangY.ZhaoX.HuT.ChenB.YinZ.MaP. X.et al (2019). Adhesive hemostatic conducting injectable composite hydrogels with sustained drug release and photothermal antibacterial activity to promote full-thickness skin regeneration during wound healing. Small15 (12), e1900046. 10.1002/smll.201900046

  • CrossRef
  • Google Scholar

• 81

  LiaoF. L.TanL.LiuH.WangJ. J.MaX. T.ZhaoB.et al (2018). Hematopoietic stem cell-derived exosomes promote hematopoietic differentiation of mouse embryonic stem cells in vitro via inhibiting the miR126/Notch1 pathway. Acta Pharmacol. Sin.39 (4), 552–560. 10.1038/aps.2017.130

  • CrossRef
  • Google Scholar

• 82

  LinY.WuJ.GuW.HuangY.TongZ.HuangL.et al (2018). Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. Adv. Sci. (Weinh)5 (4), 1700611. 10.1002/advs.201700611

  • CrossRef
  • Google Scholar

• 83

  LiuX.YangY.LiY.NiuX.ZhaoB.WangY.et al (2017). Integration of stem cell-derived exosomes with in situ hydrogel glue as a promising tissue patch for articular cartilage regeneration. Nanoscale9 (13), 4430–4438. 10.1039/c7nr00352h

  • CrossRef
  • Google Scholar

• 84

  LiuY.LiuY.ZhaoY.WuM.MaoS.CongP.et al (2022). Application of adipose mesenchymal stem cell-derived exosomes-loaded β-chitin nanofiber hydrogel for wound healing. Folia Histochem Cytobiol.60 (2), 167–178. 10.5603/FHC.a2022.0015

  • CrossRef
  • Google Scholar

• 85

  LokhandeG.CarrowJ. K.ThakurT.XavierJ. R.ParaniM.BaylessK. J.et al (2018). Nanoengineered injectable hydrogels for wound healing application. Acta Biomater.70, 35–47. 10.1016/j.actbio.2018.01.045

  • CrossRef
  • Google Scholar

• 86

  LötvallJ.HillA. F.HochbergF.BuzásE. I.Di VizioD.GardinerC.et al (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the international society for extracellular vesicles. J. Extracell. Vesicles3, 26913. 10.3402/jev.v3.26913

  • CrossRef
  • Google Scholar

• 87

  LuanX.SansanaphongprichaK.MyersI.ChenH.YuanH.SunD. (2017). Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin.38 (6), 754–763. 10.1038/aps.2017.12

  • CrossRef
  • Google Scholar

• 88

  LudwigA. K.De MiroschedjiK.DoeppnerT. R.BörgerV.RuesingJ.RebmannV.et al (2018). Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales. J. Extracell. Vesicles7 (1), 1528109. 10.1080/20013078.2018.1528109

  • CrossRef
  • Google Scholar

• 89

  LuoZ.SunY.QiB.LinJ.ChenY.XuY.et al (2022). Human bone marrow mesenchymal stem cell-derived extracellular vesicles inhibit shoulder stiffness via let-7a/Tgfbr1 axis. Bioact. Mater17, 344–359. 10.1016/j.bioactmat.2022.01.016

  • CrossRef
  • Google Scholar

• 90

  LuoZ. W.LiF. X.LiuY. W.RaoS. S.YinH.HuangJ.et al (2019). Aptamer-functionalized exosomes from bone marrow stromal cells target bone to promote bone regeneration. Nanoscale11 (43), 20884–20892. 10.1039/c9nr02791b

  • CrossRef
  • Google Scholar

• 91

  LvQ.DengJ.ChenY.WangY.LiuB.LiuJ. (2020). Engineered human adipose stem-cell-derived exosomes loaded with miR-21-5p to promote diabetic cutaneous wound healing. Mol. Pharm.17 (5), 1723–1733. 10.1021/acs.molpharmaceut.0c00177

  • CrossRef
  • Google Scholar

• 92

  MathewB.RavindranS.LiuX.TorresL.ChennakesavaluM.HuangC. C.et al (2019). Mesenchymal stem cell-derived extracellular vesicles and retinal ischemia-reperfusion. Biomaterials197, 146–160. 10.1016/j.biomaterials.2019.01.016

  • CrossRef
  • Google Scholar

• 93

  MathieuM.Martin-JaularL.LavieuG.ThéryC. (2019). Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol.21 (1), 9–17. 10.1038/s41556-018-0250-9

  • CrossRef
  • Google Scholar

• 94

  MathieuM.NévoN.JouveM.ValenzuelaJ. I.MaurinM.VerweijF. J.et al (2021). Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. Nat. Commun.12 (1), 4389. 10.1038/s41467-021-24384-2

  • CrossRef
  • Google Scholar

• 95

  MeyerC.LosaccoJ.StickneyZ.LiL.MarriottG.LuB. (2017). Pseudotyping exosomes for enhanced protein delivery in mammalian cells. Int. J. Nanomedicine12, 3153–3170. 10.2147/ijn.S133430

  • CrossRef
  • Google Scholar

• 96

  MiyasakiD. M.SenegagliaA. C.de MouraS. A. B.LeitolisA.CapriglioneL. G. A.FracaroL.et al (2022). Treatment of chronic kidney disease with extracellular vesicles from mesenchymal stem cells and CD133(+) expanded cells: A comparative preclinical analysis. Int. J. Mol. Sci.23 (5), 2521. 10.3390/ijms23052521

  • CrossRef
  • Google Scholar

• 97

  MöllerA.LobbR. J. (2020). The evolving translational potential of small extracellular vesicles in cancer. Nat. Rev. Cancer20 (12), 697–709. 10.1038/s41568-020-00299-w

  • CrossRef
  • Google Scholar

• 98

  MurphyD. E.de JongO. G.BrouwerM.WoodM. J.LavieuG.SchiffelersR. M.et al (2019). Extracellular vesicle-based therapeutics: Natural versus engineered targeting and trafficking. Exp. Mol. Med.51 (3), 1–12. 10.1038/s12276-019-0223-5

  • CrossRef
  • Google Scholar

• 99

  MurphyD. E.de JongO. G.EversM. J. W.NurazizahM.SchiffelersR. M.VaderP. (2021). Natural or synthetic RNA delivery: A stoichiometric comparison of extracellular vesicles and synthetic nanoparticles. Nano Lett.21 (4), 1888–1895. 10.1021/acs.nanolett.1c00094

  • CrossRef
  • Google Scholar

• 100

  NakamuraY.KitaS.TanakaY.FukudaS.ObataY.OkitaT.et al (2020). Adiponectin stimulates exosome release to enhance mesenchymal stem-cell-driven therapy of heart failure in mice. Mol. Ther.28 (10), 2203–2219. 10.1016/j.ymthe.2020.06.026

  • CrossRef
  • Google Scholar

• 101

  NunanR.HardingK. G.MartinP. (2014). Clinical challenges of chronic wounds: Searching for an optimal animal model to recapitulate their complexity. Dis. Model Mech.7 (11), 1205–1213. 10.1242/dmm.016782

  • CrossRef
  • Google Scholar

• 102

  NuzziR.BuonoL.ScalabrinS.De IuliisM.BussolatiB. (2021). Effect of stem cell-derived extracellular vesicles on damaged human corneal endothelial cells. Stem Cells Int.2021, 6644463. 10.1155/2021/6644463

  • CrossRef
  • Google Scholar

• 103

  OhnoS.TakanashiM.SudoK.UedaS.IshikawaA.MatsuyamaN.et al (2013). Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther.21 (1), 185–191. 10.1038/mt.2012.180

  • CrossRef
  • Google Scholar

• 104

  ParkD. J.YunW. S.KimW. C.ParkJ. E.LeeS. H.HaS.et al (2020). Improvement of stem cell-derived exosome release efficiency by surface-modified nanoparticles. J. Nanobiotechnology18 (1), 178. 10.1186/s12951-020-00739-7

  • CrossRef
  • Google Scholar

• 105

  PittengerM. F.MackayA. M.BeckS. C.JaiswalR. K.DouglasR.MoscaJ. D.et al (1999). Multilineage potential of adult human mesenchymal stem cells. Science284 (5411), 143–147. 10.1126/science.284.5411.143

  • CrossRef
  • Google Scholar

• 106

  PritchardC. C.ChengH. H.TewariM. (2012). MicroRNA profiling: Approaches and considerations. Nat. Rev. Genet.13 (5), 358–369. 10.1038/nrg3198

  • CrossRef
  • Google Scholar

• 107

  QianZ.BaiY.ZhouJ.LiL.NaJ.FanY.et al (2020). A moisturizing chitosan-silk fibroin dressing with silver nanoparticles-adsorbed exosomes for repairing infected wounds. J. Mater Chem. B8 (32), 7197–7212. 10.1039/d0tb01100b

  • CrossRef
  • Google Scholar

• 108

  RamasubramanianL.KumarP.WangA. (2019). Engineering extracellular vesicles as nanotherapeutics for regenerative medicine. Biomolecules10 (1), 48. 10.3390/biom10010048

  • CrossRef
  • Google Scholar

• 109

  ReinerA. T.WitwerK. W.van BalkomB. W. M.de BeerJ.BrodieC.CortelingR. L.et al (2017). Concise review: Developing best-practice models for the therapeutic use of extracellular vesicles. Stem Cells Transl. Med.6 (8), 1730–1739. 10.1002/sctm.17-0055

  • CrossRef
  • Google Scholar

• 110

  RenS.ChenJ.DuscherD.LiuY.GuoG.KangY.et al (2019). Microvesicles from human adipose stem cells promote wound healing by optimizing cellular functions via AKT and ERK signaling pathways. Stem Cell Res. Ther.10 (1), 47. 10.1186/s13287-019-1152-x

  • CrossRef
  • Google Scholar

• 111

  RiauA. K.OngH. S.YamG. H. F.MehtaJ. S. (2019). Sustained delivery system for stem cell-derived exosomes. Front. Pharmacol.10, 1368. 10.3389/fphar.2019.01368

  • CrossRef
  • Google Scholar

• 112

  RiazifarM.PoneE. J.LötvallJ.ZhaoW. (2017). Stem cell extracellular vesicles: Extended messages of regeneration. Annu. Rev. Pharmacol. Toxicol.57, 125–154. 10.1146/annurev-pharmtox-061616-030146

  • CrossRef
  • Google Scholar

• 113

  RihaS. M.MaarofM.FauziM. B. (2021). Synergistic effect of biomaterial and stem cell for skin tissue engineering in cutaneous wound healing: A concise review. Polym. (Basel)13 (10), 1546. 10.3390/polym13101546

  • CrossRef
  • Google Scholar

• 114

  RongY.WangZ.TangP.WangJ.JiC.ChangJ.et al (2023). Engineered extracellular vesicles for delivery of siRNA promoting targeted repair of traumatic spinal cord injury. Bioact. Mater23, 328–342. 10.1016/j.bioactmat.2022.11.011

  • CrossRef
  • Google Scholar

• 115

  SafariB.AghazadehM.DavaranS.RoshangarL. (2022). Exosome-loaded hydrogels: A new cell-free therapeutic approach for skin regeneration. Eur. J. Pharm. Biopharm.171, 50–59. 10.1016/j.ejpb.2021.11.002

  • CrossRef
  • Google Scholar

• 116

  SalunkheS.DheerajM. B.ChitkaraD.MittalA. (2020). Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance. J. Control Release326, 599–614. 10.1016/j.jconrel.2020.07.042

  • CrossRef
  • Google Scholar

• 117

  SamadikuchaksaraeiA.MehdipourA.Habibi RoudkenarM.VerdiJ.JoghataeiM. T.As'adiK.et al (2016). A dermal equivalent engineered with TGF-β3 expressing bone marrow stromal cells and amniotic membrane: Cosmetic healing of full-thickness skin wounds in rats. Artif. Organs40 (12), E266–e279. 10.1111/aor.12807

  • CrossRef
  • Google Scholar

• 118

  SandonàM.Di PietroL.EspositoF.VenturaA.SiliniA. R.ParoliniO.et al (2021). Mesenchymal stromal cells and their secretome: New therapeutic perspectives for skeletal muscle regeneration. Front. Bioeng. Biotechnol.9, 652970. 10.3389/fbioe.2021.652970

  • CrossRef
  • Google Scholar

• 119

  SchultzG. S.SibbaldR. G.FalangaV.AyelloE. A.DowsettC.HardingK.et al (2003). Wound bed preparation: A systematic approach to wound management. Wound Repair Regen.11 (1), S1–S28. 10.1046/j.1524-475x.11.s2.1.x

  • CrossRef
  • Google Scholar

• 120

  ShaoH.ImH.CastroC. M.BreakefieldX.WeisslederR.LeeH. (2018). New technologies for analysis of extracellular vesicles. Chem. Rev.118 (4), 1917–1950. 10.1021/acs.chemrev.7b00534

  • CrossRef
  • Google Scholar

• 121

  ShaoL.ZhangY.PanX.LiuB.LiangC.ZhangY.et al (2020). Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection. Cell Mol. Life Sci.77 (5), 937–952. 10.1007/s00018-019-03220-3

  • CrossRef
  • Google Scholar

• 122

  ShiA.LiJ.QiuX.SabbahM.BoroumandS.HuangT. C.et al (2021). TGF-β loaded exosome enhances ischemic wound healing in vitro and in vivo. Theranostics11 (13), 6616–6631. 10.7150/thno.57701

  • CrossRef
  • Google Scholar

• 123

  ShiQ.QianZ.LiuD.SunJ.WangX.LiuH.et al (2017). GMSC-derived exosomes combined with a chitosan/silk hydrogel sponge accelerates wound healing in a diabetic rat skin defect model. Front. Physiol.8, 904. 10.3389/fphys.2017.00904

  • CrossRef
  • Google Scholar

• 124

  ShiR.JinY.HuW.LianW.CaoC.HanS.et al (2020). Exosomes derived from mmu_circ_0000250-modified adipose-derived mesenchymal stem cells promote wound healing in diabetic mice by inducing miR-128-3p/SIRT1-mediated autophagy. Am. J. Physiol. Cell Physiol.318 (5), C848–c856. 10.1152/ajpcell.00041.2020

  • CrossRef
  • Google Scholar

• 125

  ShiX.ChengQ.HouT.HanM.SmbatyanG.LangJ. E.et al (2020). Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy. Mol. Ther.28 (2), 536–547. 10.1016/j.ymthe.2019.11.020

  • CrossRef
  • Google Scholar

• 126

  SingerA. J.ClarkR. A. (1999). Cutaneous wound healing. N. Engl. J. Med.341 (10), 738–746. 10.1056/nejm199909023411006

  • CrossRef
  • Google Scholar

• 127

  SisaC.KholiaS.NaylorJ.Herrera SanchezM. B.BrunoS.DeregibusM. C.et al (2019). Mesenchymal stromal cell derived extracellular vesicles reduce hypoxia-ischaemia induced perinatal brain injury. Front. Physiol.10, 282. 10.3389/fphys.2019.00282

  • CrossRef
  • Google Scholar

• 128

  SkogJ.WürdingerT.van RijnS.MeijerD. H.GaincheL.Sena-EstevesM.et al (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol.10 (12), 1470–1476. 10.1038/ncb1800

  • CrossRef
  • Google Scholar

• 129

  SmythT.PetrovaK.PaytonN. M.PersaudI.RedzicJ. S.GranerM. W.et al (2014). Surface functionalization of exosomes using click chemistry. Bioconjug Chem.25 (10), 1777–1784. 10.1021/bc500291r

  • CrossRef
  • Google Scholar

• 130

  SorrellJ. M.BaberM. A.CaplanA. I. (2009). Influence of adult mesenchymal stem cells on in vitro vascular formation. Tissue Eng. Part A15 (7), 1751–1761. 10.1089/ten.tea.2008.0254

  • CrossRef
  • Google Scholar

• 131

  SuD.TsaiH. I.XuZ.YanF.WuY.XiaoY.et al (2019). Exosomal PD-L1 functions as an immunosuppressant to promote wound healing. J. Extracell. Vesicles9 (1), 1709262. 10.1080/20013078.2019.1709262

  • CrossRef
  • Google Scholar

• 132

  SuY.SharmaN. S.JohnJ. V.Ganguli-IndraG.IndraA. K.GombartA. F.et al (2022). Engineered exosomes containing cathelicidin/LL-37 exhibit multiple biological functions. Adv. Healthc. Mater11, e2200849. 10.1002/adhm.202200849

  • CrossRef
  • Google Scholar

• 133

  SunB.WuF.WangX.SongQ.YeZ.MohammadniaeiM.et al (2022). An optimally designed engineering exosome-reductive COF integrated nanoagent for synergistically enhanced diabetic fester wound healing. Small18 (26), e2200895. 10.1002/smll.202200895

  • CrossRef
  • Google Scholar

• 134

  SungD. K.ChangY. S.SungS. I.AhnS. Y.ParkW. S. (2019). Thrombin preconditioning of extracellular vesicles derived from mesenchymal stem cells accelerates cutaneous wound healing by boosting their biogenesis and enriching cargo content. J. Clin. Med.8 (4), 533. 10.3390/jcm8040533

  • CrossRef
  • Google Scholar

• 135

  TabibzadehS. (2022). Repair, regeneration and rejuvenation require un-entangling pluripotency from senescence. Ageing Res. Rev.80, 101663. 10.1016/j.arr.2022.101663

  • CrossRef
  • Google Scholar

• 136

  TakeoM.LeeW.ItoM. (2015). Wound healing and skin regeneration. Cold Spring Harb. Perspect. Med.5 (1), a023267. 10.1101/cshperspect.a023267

  • CrossRef
  • Google Scholar

• 137

  TanT. T.LaiR. C.PadmanabhanJ.SimW. K.ChooA. B. H.LimS. K. (2021)., 14. Pharmaceuticals (Basel), 345. 10.3390/ph14040345Assessment of tumorigenic potential in mesenchymal-stem/stromal-cell-derived small extracellular vesicles (MSC-sEV)Pharmaceuticals4

  • CrossRef
  • Google Scholar

• 138

  TaoS. C.YuanT.ZhangY. L.YinW. J.GuoS. C.ZhangC. Q. (2017). Exosomes derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. Theranostics7 (1), 180–195. 10.7150/thno.17133

  • CrossRef
  • Google Scholar

• 139

  TheodorakiM. N.YerneniS. S.HoffmannT. K.GoodingW. E.WhitesideT. L. (2018). Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin. Cancer Res.24 (4), 896–905. 10.1158/1078-0432.Ccr-17-2664

  • CrossRef
  • Google Scholar

• 140

  ThéryC.WitwerK. W.AikawaE.AlcarazM. J.AndersonJ. D.AndriantsitohainaR.et al (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles7 (1), 1535750. 10.1080/20013078.2018.1535750

  • CrossRef
  • Google Scholar

• 141

  ThomasM. A.FaheyM. J.PuglieseB. R.IrwinR. M.AntonyakM. A.DelcoM. L. (2022). Human mesenchymal stromal cells release functional mitochondria in extracellular vesicles. Front. Bioeng. Biotechnol.10, 870193. 10.3389/fbioe.2022.870193

  • CrossRef
  • Google Scholar

• 142

  TianT.CaoL.HeC.YeQ.LiangR.YouW.et al (2021). Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia. Theranostics11 (13), 6507–6521. 10.7150/thno.56367

  • CrossRef
  • Google Scholar

• 143

  TogliattoG.DentelliP.GiliM.GalloS.DeregibusC.BiglieriE.et al (2016). Obesity reduces the pro-angiogenic potential of adipose tissue stem cell-derived extracellular vesicles (EVs) by impairing miR-126 content: Impact on clinical applications. Int. J. Obes. (Lond)40 (1), 102–111. 10.1038/ijo.2015.123

  • CrossRef
  • Google Scholar

• 144

  TohW. S.LaiR. C.ZhangB.LimS. K. (2018). MSC exosome works through a protein-based mechanism of action. Biochem. Soc. Trans.46 (4), 843–853. 10.1042/bst20180079

  • CrossRef
  • Google Scholar

• 145

  TonnesenM. G.FengX.ClarkR. A. (2000). Angiogenesis in wound healing. J. Investig. Dermatol Symp. Proc.5 (1), 40–46. 10.1046/j.1087-0024.2000.00014.x

  • CrossRef
  • Google Scholar

• 146

  TrajkovicK.HsuC.ChiantiaS.RajendranL.WenzelD.WielandF.et al (2008). Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science319 (5867), 1244–1247. 10.1126/science.1153124

  • CrossRef
  • Google Scholar

• 147

  UllahM.LiuD. D.ThakorA. S. (2019). Mesenchymal stromal cell homing: Mechanisms and strategies for improvement. iScience15, 421–438. 10.1016/j.isci.2019.05.004

  • CrossRef
  • Google Scholar

• 148

  van BalkomB. W. M.GremmelsH.GiebelB.LimS. K. (2019). Proteomic signature of mesenchymal stromal cell-derived small extracellular vesicles. Proteomics19 (1-2), e1800163. 10.1002/pmic.201800163

  • CrossRef
  • Google Scholar

• 149

  Van DeunJ.RouxQ.DevilleS.Van AckerT.RappuP.MiinalainenI.et al (2020). Feasibility of mechanical extrusion to coat nanoparticles with extracellular vesicle membranes. Cells9 (8), 1797. 10.3390/cells9081797

  • CrossRef
  • Google Scholar

• 150

  van NielG.D'AngeloG.RaposoG. (2018). Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol.19 (4), 213–228. 10.1038/nrm.2017.125

  • CrossRef
  • Google Scholar

• 151

  VuN. B.NguyenH. T.PalumboR.PellicanoR.FagooneeS.PhamP. V. (2021). Stem cell-derived exosomes for wound healing: Current status and promising directions. Minerva Med.112 (3), 384–400. 10.23736/s0026-4806.20.07205-5

  • CrossRef
  • Google Scholar

• 152

  WangC.LiangC.WangR.YaoX.GuoP.YuanW.et al (2019). The fabrication of a highly efficient self-healing hydrogel from natural biopolymers loaded with exosomes for the synergistic promotion of severe wound healing. Biomater. Sci.8 (1), 313–324. 10.1039/c9bm01207a

  • CrossRef
  • Google Scholar

• 153

  WangC.WangM.XuT.ZhangX.LinC.GaoW.et al (2019). Engineering bioactive self-healing antibacterial exosomes hydrogel for promoting chronic diabetic wound healing and complete skin regeneration. Theranostics9 (1), 65–76. 10.7150/thno.29766

  • CrossRef
  • Google Scholar

• 154

  WangL.CaiY.ZhangQ.ZhangY. (2022). Pharmaceutical activation of Nrf2 accelerates diabetic wound healing by exosomes from bone marrow mesenchymal stem cells. Int. J. Stem Cells15 (2), 164–172. 10.15283/ijsc21067

  • CrossRef
  • Google Scholar

• 155

  WangM.WangC.ChenM.XiY.ChengW.MaoC.et al (2019). Efficient angiogenesis-based diabetic wound healing/skin reconstruction through bioactive antibacterial adhesive ultraviolet shielding nanodressing with exosome release. ACS Nano13 (9), 10279–10293. 10.1021/acsnano.9b03656

  • CrossRef
  • Google Scholar

• 156

  WangX.JiaoY.PanY.ZhangL.GongH.QiY.et al (2019). Fetal dermal mesenchymal stem cell-derived exosomes accelerate cutaneous wound healing by activating Notch signaling. Stem Cells Int.2019, 2402916. 10.1155/2019/2402916

  • CrossRef
  • Google Scholar

• 157

  WebberJ.ClaytonA. (2013). How pure are your vesicles?J. Extracell. Vesicles2, 19861. 10.3402/jev.v2i0.19861

  • CrossRef
  • Google Scholar

• 158

  WiklanderO. P. B.BrennanM.LötvallJ.BreakefieldX. O.El AndaloussiS. (2019). Advances in therapeutic applications of extracellular vesicles. Sci. Transl. Med.11 (492), eaav8521. 10.1126/scitranslmed.aav8521

  • CrossRef
  • Google Scholar

• 159

  WillisG. R.KourembanasS.MitsialisS. A. (2017). Toward exosome-based therapeutics: Isolation, heterogeneity, and fit-for-purpose potency. Front. Cardiovasc Med.4, 63. 10.3389/fcvm.2017.00063

  • CrossRef
  • Google Scholar

• 160

  WitwerK. W.BuzásE. I.BemisL. T.BoraA.LässerC.LötvallJ.et al (2013). Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles2, 20360. 10.3402/jev.v2i0.20360

  • CrossRef
  • Google Scholar

• 161

  WitwerK. W.Van BalkomB. W. M.BrunoS.ChooA.DominiciM.GimonaM.et al (2019). Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J. Extracell. Vesicles8 (1), 1609206. 10.1080/20013078.2019.1609206

  • CrossRef
  • Google Scholar

• 162

  WolfP. (1967). The nature and significance of platelet products in human plasma. Br. J. Haematol.13 (3), 269–288. 10.1111/j.1365-2141.1967.tb08741.x

  • CrossRef
  • Google Scholar

• 163

  WuD.ChangX.TianJ.KangL.WuY.LiuJ.et al (2021). Bone mesenchymal stem cells stimulation by magnetic nanoparticles and a static magnetic field: Release of exosomal miR-1260a improves osteogenesis and angiogenesis. J. Nanobiotechnology19 (1), 209. 10.1186/s12951-021-00958-6

  • CrossRef
  • Google Scholar

• 164

  WuP.ZhangB.OcanseyD. K. W.XuW.QianH. (2021). Extracellular vesicles: A bright star of nanomedicine. Biomaterials269, 120467. 10.1016/j.biomaterials.2020.120467

  • CrossRef
  • Google Scholar

• 165

  XiaoT.QuH.ZengZ.LiC.WanJ. (2022). Exosomes from M2-polarized macrophages relieve oxygen/glucose deprivation/normalization-induced neuronal injury by activating the Nrf2/HO-1 signaling. Arch. Biochem. Biophys.721, 109193. 10.1016/j.abb.2022.109193

  • CrossRef
  • Google Scholar

• 166

  XiongQ. H.ZhaoL.WanG. Q.HuY. G.LiX. L. (2022). Engineered BMSCs-derived exosomal miR-542-3p promotes cutaneous wound healing. Endocr. Metab. Immune Disord. Drug Targets23, 336–346. 10.2174/1871530322666220523151713

  • CrossRef
  • Google Scholar

• 167

  XuP.XinY.ZhangZ.ZouX.XueK.ZhangH.et al (2020). Extracellular vesicles from adipose-derived stem cells ameliorate ultraviolet B-induced skin photoaging by attenuating reactive oxygen species production and inflammation. Stem Cell Res. Ther.11 (1), 264. 10.1186/s13287-020-01777-6

  • CrossRef
  • Google Scholar

• 168

  XuanW.KhanM.AshrafM. (2020). Extracellular vesicles from Notch activated cardiac mesenchymal stem cells promote myocyte proliferation and neovasculogenesis. Front. Cell Dev. Biol.8, 11. 10.3389/fcell.2020.00011

  • CrossRef
  • Google Scholar

• 169

  YanT.HuangL.YanY.ZhongY.XieH.WangX. (2022). Bone marrow mesenchymal stem cell-derived exosome miR-29b-3p alleviates UV irradiation-induced photoaging in skin fibroblast. Photodermatol. Photoimmunol. Photomed.10.1111/phpp.12827

  • CrossRef
  • Google Scholar

• 170

  YangJ.ChenZ.PanD.LiH.ShenJ. (2020). Umbilical cord-derived mesenchymal stem cell-derived exosomes combined pluronic F127 hydrogel promote chronic diabetic wound healing and complete skin regeneration. Int. J. Nanomedicine15, 5911–5926. 10.2147/ijn.S249129

  • CrossRef
  • Google Scholar

• 171

  YangY.LiC. W.ChanL. C.WeiY.HsuJ. M.XiaW.et al (2018). Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res.28 (8), 862–864. 10.1038/s41422-018-0060-4

  • CrossRef
  • Google Scholar

• 172

  YaoX.MaoY.WuD.ZhuY.LuJ.HuangY.et al (2021). Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging miR-338-5p and targeting the Wif1/Wnt8/β-catenin axis. Cancer Lett.512, 38–50. 10.1016/j.canlet.2021.04.030

  • CrossRef
  • Google Scholar

• 173

  YeoR. W.LaiR. C.ZhangB.TanS. S.YinY.TehB. J.et al (2013). Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev.65 (3), 336–341. 10.1016/j.addr.2012.07.001

  • CrossRef
  • Google Scholar

• 174

  YinK.WangS.ZhaoR. C. (2019). Exosomes from mesenchymal stem/stromal cells: A new therapeutic paradigm. Biomark. Res.7, 8. 10.1186/s40364-019-0159-x

  • CrossRef
  • Google Scholar

• 175

  YoonH. Y.KooH.KimK.KwonI. C. (2017). Molecular imaging based on metabolic glycoengineering and bioorthogonal click chemistry. Biomaterials132, 28–36. 10.1016/j.biomaterials.2017.04.003

  • CrossRef
  • Google Scholar

• 176

  YouD. G.LimG. T.KwonS.UmW.OhB. H.SongS. H.et al (2021). Metabolically engineered stem cell-derived exosomes to regulate macrophage heterogeneity in rheumatoid arthritis. Sci. Adv.7 (23), eabe0083. 10.1126/sciadv.abe0083

  • CrossRef
  • Google Scholar

• 177

  YuanR.DaiX.LiY.LiC.LiuL. (2021). Exosomes from miR-29a-modified adipose-derived mesenchymal stem cells reduce excessive scar formation by inhibiting TGF-β2/Smad3 signaling. Mol. Med. Rep.24 (5), 758. 10.3892/mmr.2021.12398

  • CrossRef
  • Google Scholar

• 178

  YuanX.LiD.ChenX.HanC.XuL.HuangT.et al (2017). Extracellular vesicles from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect against renal ischemia/reperfusion injury via delivering specificity protein (SP1) and transcriptional activating of sphingosine kinase 1 and inhibiting necroptosis. Cell Death Dis.8 (12), 3200. 10.1038/s41419-017-0041-4

  • CrossRef
  • Google Scholar

• 179

  ZhangB.YinY.LaiR. C.TanS. S.ChooA. B.LimS. K. (2014). Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev.23 (11), 1233–1244. 10.1089/scd.2013.0479

  • CrossRef
  • Google Scholar

• 180

  ZhangJ.GuanJ.NiuX.HuG.GuoS.LiQ.et al (2015). Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J. Transl. Med.13, 49. 10.1186/s12967-015-0417-0

  • CrossRef
  • Google Scholar

• 181

  ZhangW.BaiX.ZhaoB.LiY.ZhangY.LiZ.et al (2018). Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway. Exp. Cell Res.370 (2), 333–342. 10.1016/j.yexcr.2018.06.035

  • CrossRef
  • Google Scholar

• 182

  ZhangX. F.WangT.WangZ. X.HuangK. P.ZhangY. W.WangG. L.et al (2021). Hypoxic ucMSC-secreted exosomal miR-125b promotes endothelial cell survival and migration during wound healing by targeting TP53INP1. Mol. Ther. Nucleic Acids26, 347–359. 10.1016/j.omtn.2021.07.014

  • CrossRef
  • Google Scholar

• 183

  ZhangY.HaoZ.WangP.XiaY.WuJ.XiaD.et al (2019). Exosomes from human umbilical cord mesenchymal stem cells enhance fracture healing through HIF-1α-mediated promotion of angiogenesis in a rat model of stabilized fracture. Cell Prolif.52 (2), e12570. 10.1111/cpr.12570

  • CrossRef
  • Google Scholar

• 184

  ZhangY.LiuY.LiuH.TangW. H. (2019). Exosomes: Biogenesis, biologic function and clinical potential. Cell Biosci.9, 19. 10.1186/s13578-019-0282-2

  • CrossRef
  • Google Scholar

• 185

  ZhangY.ZhangP.GaoX.ChangL.ChenZ.MeiX. (2021). Preparation of exosomes encapsulated nanohydrogel for accelerating wound healing of diabetic rats by promoting angiogenesis. Mater Sci. Eng. C Mater Biol. Appl.120, 111671. 10.1016/j.msec.2020.111671

  • CrossRef
  • Google Scholar

• 186

  ZhangZ.MiT.JinL.LiM.ZhanghuangC.WangJ.et al (2022). Comprehensive proteomic analysis of exosome mimetic vesicles and exosomes derived from human umbilical cord mesenchymal stem cells. Stem Cell Res. Ther.13 (1), 312. 10.1186/s13287-022-03008-6

  • CrossRef
  • Google Scholar

• 187

  ZhaoB.ZhangX.ZhangY.LuY.ZhangW.LuS.et al (2021). Human exosomes accelerate cutaneous wound healing by promoting collagen synthesis in a diabetic mouse model. Stem Cells Dev.30 (18), 922–933. 10.1089/scd.2021.0100

  • CrossRef
  • Google Scholar

• 188

  ZhaoL.JohnsonT.LiuD. (2017). Therapeutic angiogenesis of adipose-derived stem cells for ischemic diseases. Stem Cell Res. Ther.8 (1), 125. 10.1186/s13287-017-0578-2

  • CrossRef
  • Google Scholar

• 189

  ZhouT.YuanZ.WengJ.PeiD.DuX.HeC.et al (2021). Challenges and advances in clinical applications of mesenchymal stromal cells. J. Hematol. Oncol.14 (1), 24. 10.1186/s13045-021-01037-x

  • CrossRef
  • Google Scholar

• 190

  ZhouY.ZhangX. L.LuS. T.ZhangN. Y.ZhangH. J.ZhangJ.et al (2022). Human adipose-derived mesenchymal stem cells-derived exosomes encapsulated in pluronic F127 hydrogel promote wound healing and regeneration. Stem Cell Res. Ther.13 (1), 407. 10.1186/s13287-022-02980-3

  • CrossRef
  • Google Scholar

• 191

  ZhuangZ.LiuM.LuoJ.ZhangX.DaiZ.ZhangB.et al (2022). Exosomes derived from bone marrow mesenchymal stem cells attenuate neurological damage in traumatic brain injury by alleviating glutamate-mediated excitotoxicity. Exp. Neurol.357, 114182. 10.1016/j.expneurol.2022.114182

  • CrossRef
  • Google Scholar